Summary & Overview
HCPCS Level II J8600: Melphalan Oral 2 mg
HCPCS Level II code J8600 designates oral melphalan, 2 mg, an oral chemotherapy agent used in oncology care. Nationally, accurate coding for oral oncologic agents supports appropriate claims processing, patient cost-sharing determination, and utilization monitoring as oral therapies expand in cancer treatment.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for melphalan oral therapy, common billing considerations for HCPCS Level II drug codes, and the typical sites of service where this medication is dispensed or managed. The publication summarizes benchmarks and coverage contours relevant to these payers where available and highlights policy and billing implications for outpatient pharmacy and clinic-managed oral oncology treatments.
This briefing provides clinicians, billing professionals, and policy analysts with the essential coding description, payer coverage landscape, and what to expect in claims handling for oral chemotherapy coded with J8600. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J8600 represents Melphalan; oral, 2 mg. This code indicates a prescription oral chemotherapy agent supplied in a 2 mg dosage form. Service type: Oral chemotherapy medication. Typical site of service: Outpatient pharmacy or clinic-administered oral oncology therapy.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with multiple myeloma presents to the oncology clinic for an oral chemotherapy regimen including melphalan. The oncology nurse verifies current medication list, obtains baseline complete blood count, renal and hepatic function tests, reviews prior lines of therapy and allergies, and confirms informed consent for outpatient oral antineoplastic therapy. The pharmacist compounds or dispenses J8600 (melphalan; oral, 2 mg) tablets in the prescribed total dose. The patient receives counseling on dosing schedule, adverse effects (myelosuppression, mucositis, nausea), infection precautions, and when to contact the clinic. The clinic documents administration/dispensing in the medical record, communicates with the pharmacy and payer, and schedules follow-up labs and visits to monitor response and toxicity. Typical sites of service include outpatient oncology infusion centers, hospital outpatient clinics, specialty pharmacies, and the patient’s home when medication is dispensed for self-administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard claim submission when no modifier applies |
11 |